# Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme

> **NCT00112502** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 178 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors
- Glioblastoma Multiforme

## Interventions

- **DRUG:** Celecoxib
- **DRUG:** Isotretinoin
- **DRUG:** Temozolomide
- **DRUG:** Thalidomide

## Key facts

- **NCT ID:** NCT00112502
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2021-10-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00112502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00112502, "Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00112502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*